Heren Health(300550)2024-10-24 08:07Financial Performance - The company's operating revenue for Q3 2024 was ¥103,854,630.35, representing a slight increase of 0.11% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥15,261,850.34, a decrease of 1.00% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥14,913,618.66, down 1.94%[3]. - Year-to-date net profit attributable to shareholders decreased by 92.92% to ¥929,244.29, with a year-to-date revenue decline of 6.42% to ¥264,317,028.74[3]. - Total operating revenue for Q3 2024 was CNY 264,317,028.74, a decrease of 6.4% compared to CNY 282,449,005.28 in the same period last year[13]. - Net profit for Q3 2024 was CNY 522,947.40, significantly lower than CNY 13,004,310.86 in Q3 2023, indicating a decline in profitability[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 929,244.29, a decrease from CNY 13,115,994.73 in the previous period[15]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of ¥115,425,086.86, a decrease of 20.33% compared to the previous year[3]. - The net cash flow from operating activities for Q3 2024 is -CNY 115,425,086.86, compared to -CNY 95,927,471.87 in the same period last year[17]. - Cash inflow from operating activities totaled CNY 131,808,331.68, down from CNY 252,632,718.17 in the previous year[17]. - Cash outflow from operating activities reached CNY 247,233,418.54, a decrease from CNY 348,560,190.04 year-over-year[17]. - As of September 30, 2024, the company's cash and cash equivalents amounted to ¥482,414,027.65, a decrease from ¥555,323,304.95 at the beginning of the period, representing a decline of approximately 13.1%[11]. - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 476,886,509.12, compared to CNY 412,296,423.36 at the end of the previous year[17]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,435,932,726.15, reflecting a decrease of 0.17% from the end of the previous year[3]. - The total assets decreased slightly to CNY 1,435,932,726.15 from CNY 1,438,378,630.67, reflecting a stable asset base[13]. - The total liabilities decreased to CNY 353,013,879.33 from CNY 357,905,927.02, indicating a reduction in financial obligations[13]. - The company's equity attributable to shareholders decreased by 0.64% to ¥1,072,323,055.60 compared to the end of the previous year[3]. - The company's equity attributable to shareholders decreased to CNY 1,072,323,055.60 from CNY 1,079,270,615.54, reflecting the impact of lower profits[13]. Investments and Expenses - The company reported a significant increase in prepayments, which rose by 461.21% to ¥9,261,272.84, attributed to increased procurement payments[6]. - The company’s long-term equity investments surged by 165,945.17% to ¥3,166,049.62 due to increased investment in Zhongyuan Heren[6]. - The company experienced a 1557.92% increase in credit impairment losses, amounting to -¥22,538,003.98, primarily influenced by sales collection issues[6]. - The company reported a decrease in financial expenses by 53.33% to -¥4,025,806.35, mainly due to reduced interest income[6]. - Research and development expenses increased to CNY 38,564,331.96 from CNY 37,478,001.90, highlighting continued investment in innovation[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,299, with the largest shareholder, Tongce Medical Co., holding 19.01% of shares[8]. - The company reported a total of 295,230 restricted shares at the beginning of the period, with 51,450 shares released from restrictions during the period[9]. - The largest shareholder, Tongce Medical Co., held 49,920,315 shares, representing 19.01% of the total shares[8]. - The company has a total of 40,260,815 shares held by Hangzhou Panyuan Investment Co., accounting for 15.33% of the total shares[8]. Operational Changes - The company terminated the "Smart Hospital Integrated Construction Project" and will permanently supplement the remaining raised funds into working capital, following approval at the September 9, 2024, shareholders' meeting[10].